upfront pd-1 inhibitor monotherapy in advanced nsclc
Published 5 years ago • 93 plays • Length 4:16Download video MP4
Download video MP3
Similar videos
-
4:55
long-term outcomes with pd-1 monotherapy in nsclc
-
5:27
pd-1 inhibitors in nsclc: combination or monotherapy
-
6:10
pd-1 inhibitor use in advanced lung cancer
-
7:22
pd-1 inhibition in lung cancer
-
6:53
upfront pd-l1 blockade in newly diagnosed nsclc
-
10:32
upfront pd-1 inhibitor treatment for nsclc: a new paradigm
-
4:25
pd-1/pd-l1 inhibitors explored across nsclc settings
-
5:43
duration of upfront immunotherapy for nsclc
-
1:23
dr. scott gettinger on the pd-1 inhibitor bms-936558 in non-small cell lung cancer
-
6:36
patient selection for upfront immunotherapy in nsclc
-
1:15
dr. rizvi on pd-1 and pd-l1 inhibitors in lung cancer
-
2:19
the future of anti-pd-1 therapies in the nsclc treatment landscape
-
8:03
studies in anti-pd-l1 monotherapy for nsclc - lung cancer onctalk 2022
-
4:36
efficacy and safety of checkpoint inhibitors in lung cancer
-
5:36
first-line therapy in pd-l1–advanced nsclc
-
1:02
dr. herbst on pd-1 inhibitors in lung cancer
-
1:29
dr. borghaei on the clinical utility of pd-l1 in advanced nsclc
-
6:04
checkmate 227: tmb versus pd-l1 in advanced-stage nsclc
-
8:44
upfront immunotherapy for pd-l1 nsclc